3 results
Approved WMOPending
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren*s syndrome (pSS) versus placebo.
Approved WMORecruiting
The primary objective of this study is to evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI).
Approved WMORecruiting
Primary objective:• Systemic immunogenicity of the DCP-001 vaccination in high grade serous ovarian (HGSOC) cancer patients.